Shares in Valeritas (NSDQ:VLRX) fell today after the medical technology company announced its preliminary financial results for the third quarter of 2018.
The Bridgewater, N.J.-based company said it expects to post quarterly revenue of approximately $6.9 million, just ahead of the $6.85 million predicted by analysts. Compared to the same period in 2017, Valeritas’ sales are up 36%.
Get the full story at our sister site, Drug Delivery Business News.
The post Valeritas shares fall despite Street-beating Q3 prelims appeared first on MassDevice.